"目录号: HY-13998
Anti-infection-
ABT-333 是一种非核苷抑制剂，抑制RNA依赖性的HCV NS5B基因编码的 RNA 聚合酶，抑制 HCV 基因型 1a 和 1b 临床分离株衍生的重组 NS5B 聚合酶，IC50为 2.2 到 10.7 nM。
HCV
相关产品
Asunaprevir-PSI-7977-Simeprevir-Daclatasvir-Paritaprevir-Telaprevir-Boceprevir-Ledipasvir-Ombitasvir-MK-5172-Elbasvir-Ribavirin-R-1479-Balapiravir-Artemisinin-
生物活性
Description
ABT-333 is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by theHCV NS5Bgene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, withIC50between 2.2 and 10.7 nM.
IC50& Target
IC50: 2.2-10.7 nM (NS5B polymerase)[1]
In Vitro
ABT-333 (Dasabuvir) is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases. ABT-333 (Dasabuvir) inhibits the polymerase enzymatic activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s between 2.2 and 10.7 nM. ABT-333 inhibits replication of HCV subgenomic replicons in cell culture assays, with EC50values of 7.7 and 1.8 nM against genotype 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, there is a 12- to 13-fold decrease in inhibitory potency, yielding EC50s of 99 and 21 nM for HCV genotype 1a (H77) and 1b (Con1) replicons, respectively[1].
Clinical Trial
NCT02052349
AbbVie
Relative Bioavailability
November 2013
Phase 1
NCT01704755
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection-Compensated Cirrhosis
October 2012
Phase 3
NCT02534870
AbbVie
Healthy Volunteer
September 2015
Phase 1
NCT00895102
Abbott
HCV Infection
April 2009
Phase 1
NCT01674725
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
August 2012
Phase 3
NCT00909636
Abbott
HCV Infection
May 2009
Phase 1
NCT00726882
AbbVie (prior sponsor, Abbott)-AbbVie
HCV Infection
August 2008
Phase 2
NCT01911845
AbbVie
Chronic Hepatitis C Infection-Chronic Hepatitis C
April 2013
Phase 2
NCT00851890
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Virus Infection
March 2009
Phase 2
NCT00919490
Abbott-Abbott Japan Co.,Ltd
HCV Infections
June 2009
Phase 1
NCT01306617
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection-Hepatitis C-Hepatitis C Virus
February 2011
Phase 2
NCT02167945
AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
June 12, 2014
Phase 3
NCT02219490
AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
October 30, 2014
Phase 3
NCT02517515
AbbVie
Chronic Hepatitis C Virus
July 16, 2015
Phase 3
NCT01767116
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
December 2012
Phase 3
NCT01074008
AbbVie (prior sponsor, Abbott)-AbbVie
Hepatitis C-HCV-Chronic Hepatitis C Infection-Hepatitis C Genotype 1
March 2010
Phase 2
NCT01833533
AbbVie
Chronic Hepatitis C Infection
March 2013
Phase 3
NCT02517528
AbbVie
Chronic Hepatitis C Virus
July 2015
Phase 3
NCT01716585
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
November 2012
Phase 3
NCT01715415
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
November 2012
Phase 3
NCT00696904
Abbott
HCV Infection
June 2008
Phase 1
NCT00768690
Abbott
HCV Infection
October 2008
Phase 1
NCT01939197
AbbVie
Hepatitis C Virus Infection-Human Immunodeficiency Virus Infection-Chronic Hepatitis C-Compensated Cirrhosis and Non-cirrhotics
August 2013
Phase 3
NCT01464827
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C-Hepatitis C (HCV)-Hepatitis C Genotype 1
October 2011
Phase 2
NCT01854528
AbbVie
Chronic Hepatitis C Infection
June 2013
Phase 3
NCT01563536
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
February 2012
Phase 2
NCT01854697
AbbVie
Chronic Hepatitis C Infection
March 2013
Phase 3
NCT01782495
AbbVie
Chronic Hepatitis C Infection
February 25, 2013
Phase 2
NCT01773070
AbbVie (prior sponsor, Abbott)-AbbVie
Hepatitis C
June 2013
Phase 3
NCT01995071
AbbVie
Chronic Hepatitis C-Hepatitis C Virus-Compensated Cirrhosis
November 2013
Phase 2
NCT02734173
Ottawa Hospital Research Institute-AbbVie
Hepatitis C
July 2015
Phase 4
NCT02052349
AbbVie
Relative Bioavailability
November 2013
Phase 1
NCT01704755
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection-Compensated Cirrhosis
October 2012
Phase 3
NCT02534870
AbbVie
Healthy Volunteer
September 2015
Phase 1
NCT00895102
Abbott
HCV Infection
April 2009
Phase 1
NCT01674725
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
August 2012
Phase 3
NCT00909636
Abbott
HCV Infection
May 2009
Phase 1
NCT00726882
AbbVie (prior sponsor, Abbott)-AbbVie
HCV Infection
August 2008
Phase 2
NCT01911845
AbbVie
Chronic Hepatitis C Infection-Chronic Hepatitis C
April 2013
Phase 2
NCT00851890
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Virus Infection
March 2009
Phase 2
NCT00919490
Abbott-Abbott Japan Co.,Ltd
HCV Infections
June 2009
Phase 1
NCT01306617
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection-Hepatitis C-Hepatitis C Virus
February 2011
Phase 2
NCT02167945
AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
June 12, 2014
Phase 3
NCT02219490
AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
October 30, 2014
Phase 3
NCT02517515
AbbVie
Chronic Hepatitis C Virus
July 16, 2015
Phase 3
NCT01767116
AbbVie (prior sponsor, Abbott)-AbbVie
Chronic Hepatitis C Infection
December 2012
Phase 3
NCT01074008
AbbVie (prior sponsor, Abbott)-AbbVie
Hepatitis C-HCV-Chronic Hepatitis C Infection-Hepatitis C Genotype 1
March 2010
Phase 2
NCT01833533
AbbVie
Chronic Hepatitis C Infection
March 2013
Phase 3
NCT02517528
AbbVie
Chronic Hepatitis C Virus
July 2015
Phase 3